Frontiers in Hematology

Case Report

Accepted on 04 Feb 2025

Acquired von Willebrand Disease associated with Smoldering Multiple Myeloma and Hereditary Hemorrhagic Telangiectasia successfully treated with Daratumumab, Pomalidomide, and Dexamethasone: Hitting three birds with one stone?case report

in Blood Cancer

Lemchukwu Amaeshi
Mansour Gergi
Jacqueline Poston

Frontiers in Hematology

doi 10.3389/frhem.2025.1499500

Original Research

Accepted on 04 Feb 2025

FACIT-Fatigue Scale in Patients with Cold Agglutinin Disease: Psychometric Validation and Estimation of Clinically Meaningful Change

in Red Cells, Iron and Erythropoiesis

David Cella
Quentin A Hill
Alia Karaouni
Florence Joly
Timothee Sourdille
Frank Shafer
Marek Wardęcki
Mark Kosinski
Alexander Röth

Frontiers in Hematology

doi 10.3389/frhem.2025.1490130

Original Research

Accepted on 04 Feb 2025

Time to Initiation of Antiresorptive Agents in Multiple Myeloma to Reduce Skeletal Related Events

in Blood Cancer

Amman Bhasin
Adam Finn Binder
Leland Damron
Amry Majeed
Adam Barsouk
Kelly Hughes
Niketa Raj
Abdullateef O Abdulkareem
Tingting Zhan
Divya Polu

Frontiers in Hematology

doi 10.3389/frhem.2025.1521017

Mini Review

Accepted on 03 Feb 2025

The role of Glucocorticoids in Erythropoiesis

in Red Cells, Iron and Erythropoiesis

Lars Lee Perry Hanssen
Deena Iskander

Frontiers in Hematology

doi 10.3389/frhem.2025.1540152

Editorial

Published on 24 Jan 2025

Editorial: Two decades of targeted therapies in hematology: new targets and novel combinations

in Immunobiology and Immunotherapy

Bruno António Cardoso
Natalia Neparidze

Frontiers in Hematology

doi 10.3389/frhem.2025.1548984

242 views

Original Research

Published on 21 Jan 2025

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

in Blood Cancer

Sam Salek
Samantha Nier
Zack Pemberton-Whiteley
Tatyana Ionova
Giuseppe Ianni
Giovanni Tripepi
Nick York
Nicole Schroeter
Kathryn Huntley
Michael Rynne

Frontiers in Hematology

doi 10.3389/frhem.2024.1502166

547 views

Case Report

Published on 16 Jan 2025

Case report: VEXAS syndrome: first documented cases in Latin America

in Blood Cancer

Carolina Ottati
Inés Gervaz
Martín Yandian
Matilde Boada
Gabriela Vidal-Senmache
Percy Ortiz-Guerra
Ana I. Catalán
Patricia Kutscher
Diego Lopez
Lilian Diaz

Frontiers in Hematology

doi 10.3389/frhem.2024.1501337

151 views

Case Report

Published on 10 Jan 2025

Case report: A decade-long journey with cyclic thrombocytopenia

in Blood Cancer

Talal Al-Assil
Suhaib Ellythy
Omer A. Idris
Mohammad Omaira

Frontiers in Hematology

doi 10.3389/frhem.2024.1482891

173 views

Mini Review

Accepted on 02 Jan 2025

The aging hematopoietic stem cell niche: a mini review

in Hematopoiesis and Stem Cells

Xin Gao
Jing Zhang
Owen James Tamplin

Frontiers in Hematology

doi 10.3389/frhem.2025.1525132

Original Research

Published on 26 Dec 2024

Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathology

in Immunobiology and Immunotherapy

Luce Perie
Selina Stippa
Christoph Saffer
Andrea Hartmann
Mathias Mörgelin
Svante L. H. Zipfel
Marc Thilo Figge
Thorsten Wiech
Christine Skerka
Peter F. Zipfel

Frontiers in Hematology

doi 10.3389/frhem.2024.1469176

449 views

Mini Review

Published on 24 Dec 2024

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

in Blood Cancer

Joshua W. Bliss
Spencer Krichevsky
Joseph Scandura
Ghaith Abu-Zeinah

Frontiers in Hematology

doi 10.3389/frhem.2024.1504327

398 views

Case Report

Published on 17 Dec 2024

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

in Blood Cancer

Monika A. Satoskar
Matthew R. Lordo
Daniel M. Jones
Nicholas B. Nowacki
Jonathan E. Brammer
John C. Reneau
Timothy J. Voorhees

Frontiers in Hematology

doi 10.3389/frhem.2024.1463487

327 views

Case Report

Published on 12 Dec 2024

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

in Blood Cancer

Selene Grano
Valentina Bonuomo
Diana Carli
Veronica Peri
Loredana Farinasso
Ugo Ramenghi
Daniela Cilloni
Carmen Fava

Frontiers in Hematology

doi 10.3389/frhem.2024.1508463

199 views

Case Report

Published on 09 Dec 2024

Case report: Vitamin B12 deficiency-associated hemolytic anemia

in Red Cells, Iron and Erythropoiesis

Chiranjeevi Sainatham
Paul Stendahl Dy
Sharanya Kaushik
Jayanth Reddy Tallapalli
Viral Patel
Vishal Jindal
Sonal Paul

Frontiers in Hematology

doi 10.3389/frhem.2024.1446241

744 views

Study Protocol

Published on 06 Dec 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

in Blood Cancer

Theo Leitner
Evgenii Shumilov
Christina Schwitlick
Raphael Koch
Franziska Hamm
Marion Högner
Florian Bassermann
Katja Weisel
Hermann Einsele
Martin Kortüm

Frontiers in Hematology

doi 10.3389/frhem.2024.1436845

645 views

Original Research

Published on 05 Dec 2024

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

in Blood Cancer

Manuel Neves
Rita Gerivaz
Graça Esteves
Rui Bergantim
Gisela Ferreira
Henrique Coelho
Celina Afonso
Delfim Duarte
Anabela Neves
Helena Matos Silva

Frontiers in Hematology

doi 10.3389/frhem.2024.1480120

383 views

Navigation group

Articles

Acquired von Willebrand Disease associated with Smoldering Multiple Myeloma and Hereditary Hemorrhagic Telangiectasia successfully treated with Daratumumab, Pomalidomide, and Dexamethasone: Hitting three birds with one stone?case report

FACIT-Fatigue Scale in Patients with Cold Agglutinin Disease: Psychometric Validation and Estimation of Clinically Meaningful Change

Time to Initiation of Antiresorptive Agents in Multiple Myeloma to Reduce Skeletal Related Events

The role of Glucocorticoids in Erythropoiesis

Editorial: Two decades of targeted therapies in hematology: new targets and novel combinations

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

Case report: VEXAS syndrome: first documented cases in Latin America

Case report: A decade-long journey with cyclic thrombocytopenia

The aging hematopoietic stem cell niche: a mini review

Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathology

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

Case report: Vitamin B12 deficiency-associated hemolytic anemia

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study